Back to All Combinations

APC + KRAS + TP53 + SMAD4

Poor Prognosis
12.00% Prevalence Level 2B TP53 Combinations
Genes Involved
APC KRAS TP53 SMAD4
Treatment Implications

SMAD4 loss = poor prognosis, liver mets.

Recommended Treatments
FOLFOXIRI + Bevacizumab
Clinical trials
Treatments to Avoid

No specific contraindications noted

Study References

TCGA

Key Statistics
12.00%
Prevalence in CRC
No
Targetable
Clinical Notes
Aggressive treatment warranted.
Information

Category: TP53 Combinations

Evidence Level: Level 2B

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.